TELA Bio Reports First Quarter 2025 Financial Results

Rhea-AI Summary

TELA Bio (TELA) reported Q1 2025 financial results with revenue of $18.5 million, representing 12% year-over-year growth and 5% sequential growth. The company's OviTex and OviTex PRS products saw revenue increases of 15% and 2% respectively. TELA Bio launched larger-sized OviTex PRS for plastic and reconstructive surgery.

Gross profit reached $12.5 million (67.6% margin), while operating expenses decreased to $22.9 million. The company reported a net loss of $11.3 million. Cash and equivalents stood at $42.8 million as of March 31, 2025. TELA Bio reiterated its 2025 revenue guidance of $85.0-88.0 million, projecting 23-27% growth, with operating expenses expected to remain flat compared to 2024.

Positive

• Revenue grew 12% YoY to $18.5 million, with 5% sequential growth
• OviTex product line revenue increased 15% YoY
• Operating expenses decreased from $23.7M to $22.9M due to efficiency efforts
• Strong 2025 guidance projecting 23-27% revenue growth
• Launch of larger-sized OviTex PRS product to simplify complex procedures

Negative

• Net loss increased to $11.3M from $5.7M in Q1 2024
• Gross margin declined to 67.6% from 68.3% due to inventory adjustments
• Decrease in average selling prices due to product mix changes
• OviTex PRS showed minimal growth of only 2% YoY

Insights

Financial Analyst specializing in MedTech

TELA Bio reports solid 12% revenue growth but widened operating losses; maintained guidance signals confidence despite profitability challenges.

TELA Bio's Q1 2025 results reveal a company gaining momentum on the revenue front while still navigating profitability challenges. The $18.5 million in quarterly revenue represents 12% year-over-year growth and 5% sequential improvement from Q4 2024. Their core OviTex product line performed particularly well with 15% growth, while OviTex PRS increased more modestly at 2%.

The gross margin story shows slight pressure, dipping to 67.6% from 68.3% a year ago, primarily due to inventory adjustments. This minor erosion bears watching but isn't yet cause for alarm. More concerning is the operating loss of $10.5 million versus $4.8 million in Q1 2024, though this comparison is skewed by a one-time $7.6 million gain from asset sales last year.

On the positive side, operating expenses decreased to $22.9 million from $23.7 million, reflecting efficiency initiatives from Q3 2024. However, these expenses still substantially exceed the $12.5 million gross profit, highlighting the significant gap to profitability. With $42.8 million in cash reserves, the company has runway to pursue its growth strategy, but careful cash management remains essential.

Management's confidence is evident in their maintained full-year revenue guidance of $85-88 million, implying 23-27% annual growth and acceleration in coming quarters. The company's strategic focus on robotically compatible products aligns with industry trends but has pressured average selling prices.

The recent launch of larger-sized OviTex PRS products represents a potential growth driver by simplifying complex procedures in plastic and reconstructive surgery. Meanwhile, the reorganized sales structure appears to be delivering on new account acquisition and market penetration goals.

MALVERN, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2025.

Recent Highlights

• Delivered revenue of $18.5 million in the first quarter 2025, representing growth of 12% over the prior year period and sequential growth of 5% over the fourth quarter of 2024;
• Increased demand for OviTex^® and OviTex PRS Reinforced Tissue Matrix products during the first quarter, resulting in year-over-year revenue increase for each product of approximately 15% and 2%, respectively;
• Commenced full U.S. commercial launch of larger sized OviTex PRS for use in plastic and reconstructive surgery, which may reduce the need for multiple small pieces and have the potential to simplify more complex plastic and reconstructive procedures;
• Reiterated full year 2025 revenue guidance of $85.0 million to $88.0 million, representing 23% to 27% year-over-year growth.

“We are pleased with the strong performance in the first quarter of 2025 following the realignment and optimization of our sales organization,” said Antony Koblish, President and CEO of TELA Bio. “The complementary dynamic between our Territory Managers and Account Specialists enabled new account wins and greater market penetration across our product portfolio. We are focused on carrying this momentum throughout 2025 as we aim to drive higher revenue growth and increased operating leverage and continue to drive towards profitability.”

First Quarter 2025 Financial Results

Revenue was $18.5 million in the first quarter of 2025, an increase of 12% compared to the same period in 2024. The increase was due to an increase in unit sales of our hernia products resulting from the addition of new customers and growing international sales. This growth was partially offset by a decrease in average selling prices caused by product mix as the share of smaller-sized units increased following the introduction of robotically compatible OviTex IHR and our increased focus on growing market share in high-volume minimally invasive and robotic procedures.

Gross profit was $12.5 million in the first quarter of 2025, or 67.6% of revenue, compared to $11.3 million, or 68.3% of revenue, in the same period in 2024. The decrease in gross margin was primarily due to greater excess and obsolete inventory adjustments as a percentage of revenue.

Operating expenses were $22.9 million in the first quarter of 2025, compared to $23.7 million in the same period in 2024. The decrease was due to lower compensation costs resulting from efficiency efforts initiated in the third quarter of 2024, partially offset by higher commissions on an increased revenue base, higher study and outside development costs, and increased professional fees.

Loss from operations was $10.5 million in the first quarter of 2025, compared to a loss from operations of $4.8 million in the same period in 2024. The prior year period included the recognition of a gain of $7.6 million for the sale of certain assets related to the NIVIS Fibrillar Collagen Pack Device to MiMedx in March 2024.

Net loss was $11.3 million in the first quarter of 2025, compared to a net loss of $5.7 million in the same period in 2024.

Cash and cash equivalents on March 31, 2025 totaled $42.8 million.

2025 Financial Guidance Reiterated

• Full year 2025 revenue is projected to range from $85.0 million to $88.0 million, representing growth of 23% to 27% over full year 2024.
• 2025 operating expenses are expected to be flat to 2024.

Conference Call

TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 8, 2025 to discuss its first quarter financial results. Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA Bio's website.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full year 2025 and reduction in operating expenses throughout the full year 2025 compared to prior periods. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs and trade protection measures, and inflationary pressures, potentially impacting our ability to market our products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures, labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; product development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact
Louisa Smith
ir@telabio.com

TELA Bio, Inc. Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited)
	March 31,				December 31,
	2025				2024
Assets
Current assets:
Cash and cash equivalents	$	42,833			$	52,670
Accounts receivable, net of allowances of $267 and $275		10,557				10,098
Inventory		13,533				12,781
Prepaid expenses and other current assets		2,822				2,522
Total current assets		69,745				78,071
Property and equipment, net		2,201				2,341
Intangible assets, net		1,644				1,739
Right-of-use assets		1,678				1,738
Other long-term assets		1,626				2,276
Deferred tax asset, net		92				140
Restricted cash		265				265
Total assets	$	77,251			$	86,570
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	4,002			$	2,147
Accrued expenses and other current liabilities		12,534				13,451
Total current liabilities		16,536				15,598
Long‑term debt		41,275				41,124
Other long‑term liabilities		1,317				1,390
Total liabilities		59,128				58,112
Stockholders’ equity:
Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding		—				—
Common stock; $0.001 par value: 200,000,000 shares authorized; 39,554,771 and 39,395,712 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively		40				39
Additional paid-in capital		387,986				387,059
Accumulated other comprehensive income		91				90
Accumulated deficit		(369,994	)			(358,730	)
Total stockholders’ equity		18,123				28,458
Total liabilities and stockholders’ equity	$	77,251			$	86,570

TELA Bio, Inc. Consolidated Statements of Operations and Comprehensive Loss (In thousands, except share and per share amounts) (Unaudited)
	Three months ended March 31,
	2025				2024
Revenue	$	18,520			$	16,603
Cost of revenue (excluding amortization of intangible assets)		5,913				5,172
Amortization of intangible assets		95				95
Gross profit		12,512				11,336
Operating expenses:
Sales and marketing		16,608				17,520
General and administrative		3,836				3,829
Research and development		2,540				2,393
Total operating expenses		22,984				23,742
Other operating income:
Gain on sale of product line		—				7,580
Loss from operations		(10,472	)			(4,826	)
Other (expense) income:
Interest expense		(1,219	)			(1,332	)
Other income		479				497
Total other expense, net		(740	)			(835	)
Loss before income tax expense		(11,212	)			(5,661	)
Income tax expense		(52	)			—
Net loss	$	(11,264	)		$	(5,661	)
Net loss per common share, basic and diluted	$	(0.25	)		$	(0.23	)
Weighted average common shares outstanding, basic and diluted		45,267,020				24,579,386
Comprehensive loss:
Net loss	$	(11,264	)		$	(5,661	)
Foreign currency translation adjustment		1				6
Comprehensive loss	$	(11,263	)		$	(5,655	)

FAQ

What was TELA Bio's (TELA) revenue in Q1 2025?

TELA Bio reported revenue of $18.5 million in Q1 2025, representing 12% year-over-year growth and 5% sequential growth from Q4 2024.

What is TELA Bio's (TELA) revenue guidance for 2025?

TELA Bio reiterated its full-year 2025 revenue guidance of $85.0-88.0 million, representing growth of 23-27% over 2024.

How much cash does TELA Bio (TELA) have as of Q1 2025?

TELA Bio reported cash and cash equivalents of $42.8 million as of March 31, 2025.

What was TELA Bio's (TELA) net loss in Q1 2025?

TELA Bio reported a net loss of $11.3 million in Q1 2025, compared to a net loss of $5.7 million in Q1 2024.

How did TELA Bio's OviTex products perform in Q1 2025?

OviTex products saw a 15% year-over-year revenue increase, while OviTex PRS products showed a 2% year-over-year revenue increase.